المؤلفون: Sondergeld, P., van de Donk, N. W. C. J., Richardson, P. G., Plesner, T.

المصدر: Sondergeld , P , van de Donk , N W C J , Richardson , P G & Plesner , T 2015 , ' Monoclonal antibodies in myeloma ' , Clinical Advances in Hematology & Oncology , vol. 13 , no. 9 , pp. 599-609 . < http://www.hematologyandoncology.net/index.php/archives/september-2015/monoclonal-antibodies-inTest-myeloma/ >

مصطلحات موضوعية: antineoplastic activity article cancer incidence cell adhesion complement dependent cytotoxicity diarrhea fatigue human immune response *multiple myeloma/dt [Drug Therapy] nausea neutropenia peripheral neuropathy personalized medicine protein expression signal transduction thrombocytopenia tumor microenvironment ave 1642 bevacizumab bortezomib carfilzomib CD38 antigen CD56 antigen cixutumumab dacetuzumab daratumumab/ct [Clinical Trial] daratumumab/dt [Drug Therapy] denosumab dexamethasone elotuzumab/ct [Clinical Trial] elotuzumab/dt [Drug Therapy] figitumumab indatuximab ravtansine/ct [Clinical Trial] indatuximab ravtansine/dt [Drug Therapy] isatuximab/ct [Clinical Trial] isatuximab/dt [Drug Therapy] lenalidomide lorvotuzumab mertansine/ct [Clinical Trial] lorvotuzumab mertansine/dt [Drug Therapy] melphalan milatuzumab *monoclonal antibody/ec [Endogenous Compound] pidilizumab rituximab samalizumab siltuximab syndecan 1/ct [Clinical Trial] syndecan 1/dt [Drug Therapy] tabalumab vorsetuzumab

العلاقة: https://portal.findresearcher.sdu.dk/da/publications/daa778e9-5aac-4561-9d5d-b296eb862a36Test

الإتاحة: https://portal.findresearcher.sdu.dk/da/publications/daa778e9-5aac-4561-9d5d-b296eb862a36Test
http://www.hematologyandoncology.net/index.php/archives/september-2015/monoclonal-antibodies-inTest-myeloma/

مصطلحات الفهرس: male, malignant neoplasm/dt [Drug Therapy], medication compliance, medication error, medication therapy management, metastasis/dt [Drug Therapy], multiple cycle treatment, multiple myeloma/dt [Drug Therapy], pneumocystosis/dt [Drug Therapy], pneumocystosis/pc [Prevention], potentially inappropriate medication, quality control, randomized controlled trial (topic), review, solid malignant neoplasm/dt [Drug Therapy], stomach cancer/dt [Drug Therapy], systematic review, teleconsultation, thrombosis prevention, venous thromboembolism/dt [Drug Therapy], venous thromboembolism/pc [Prevention], abiraterone/dt [Drug Therapy], abiraterone/pv [Special Situation for Pharmacovigilance], antiemetic agent/ae [Adverse Drug Reaction], antiemetic agent/dt [Drug Therapy], antifungal agent/dt [Drug Therapy], antiinfective agent, antineoplastic agent/ae [Adverse Drug Reaction], antineoplastic agent/ct [Clinical Trial], antineoplastic agent/do [Drug Dose], antineoplastic agent/dt [Drug Therapy], antineoplastic agent/iv [Intravenous Drug Administration], antineoplastic agent/po [Oral Drug Administration], antineoplastic agent/pa [Parenteral Drug Administration], antineoplastic agent/pv [Special Situation for Pharmacovigilance], antithrombocytic agent/dt [Drug Therapy], bicalutamide/dt [Drug Therapy], bicalutamide/pv [Special Situation for Pharmacovigilance], bisphosphonic acid derivative, calcium, corticosteroid, dexamethasone/pv [Special Situation for Pharmacovigilance], enzalutamide/dt [Drug Therapy], enzalutamide/pv [Special Situation for Pharmacovigilance], erlotinib/pv [Special Situation for Pharmacovigilance], gefitinib/pv [Special Situation for Pharmacovigilance], gimeracil plus oteracil potassium plus tegafur/dt [Drug Therapy], gimeracil plus oteracil potassium plus tegafur/pv [Special Situation for Pharmacovigilance], influenza vaccine, ondansetron/pv [Special Situation for Pharmacovigilance], vitamin D, drug choice, adjuvant chemotherapy, adjuvant therapy, adult, adverse drug reaction/si [Side Effect], aged, antibiotic prophylaxis, cancer chemotherapy, cancer immunotherapy, cancer palliative therapy, castration resistant prostate cancer/dt [Drug Therapy], chemotherapy induced nausea and vomiting/dt [Drug Therapy], chemotherapy induced nausea and vomiting/si [Side Effect], clinical pharmacy, controlled study, corticosteroid therapy, drug interaction, female, follow up, health care planning, human, influenza vaccination, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28684Test
Journal of Pharmacy Practice and Research
Click here for full text options
LibKey Link

مصطلحات الفهرس: male, malignant neoplasm/dt [Drug Therapy], medication compliance, medication error, medication therapy management, metastasis/dt [Drug Therapy], multiple cycle treatment, multiple myeloma/dt [Drug Therapy], pneumocystosis/dt [Drug Therapy], pneumocystosis/pc [Prevention], potentially inappropriate medication, quality control, randomized controlled trial (topic), review, solid malignant neoplasm/dt [Drug Therapy], stomach cancer/dt [Drug Therapy], systematic review, teleconsultation, thrombosis prevention, venous thromboembolism/dt [Drug Therapy], venous thromboembolism/pc [Prevention], abiraterone/dt [Drug Therapy], abiraterone/pv [Special Situation for Pharmacovigilance], antiemetic agent/ae [Adverse Drug Reaction], antiemetic agent/dt [Drug Therapy], antifungal agent/dt [Drug Therapy], antiinfective agent, antineoplastic agent/ae [Adverse Drug Reaction], antineoplastic agent/ct [Clinical Trial], antineoplastic agent/do [Drug Dose], antineoplastic agent/dt [Drug Therapy], antineoplastic agent/iv [Intravenous Drug Administration], antineoplastic agent/po [Oral Drug Administration], antineoplastic agent/pa [Parenteral Drug Administration], antineoplastic agent/pv [Special Situation for Pharmacovigilance], antithrombocytic agent/dt [Drug Therapy], bicalutamide/dt [Drug Therapy], bicalutamide/pv [Special Situation for Pharmacovigilance], bisphosphonic acid derivative, calcium, corticosteroid, dexamethasone/pv [Special Situation for Pharmacovigilance], enzalutamide/dt [Drug Therapy], enzalutamide/pv [Special Situation for Pharmacovigilance], erlotinib/pv [Special Situation for Pharmacovigilance], gefitinib/pv [Special Situation for Pharmacovigilance], gimeracil plus oteracil potassium plus tegafur/dt [Drug Therapy], gimeracil plus oteracil potassium plus tegafur/pv [Special Situation for Pharmacovigilance], influenza vaccine, ondansetron/pv [Special Situation for Pharmacovigilance], vitamin D, drug choice, adjuvant chemotherapy, adjuvant therapy, adult, adverse drug reaction/si [Side Effect], aged, antibiotic prophylaxis, cancer chemotherapy, cancer immunotherapy, cancer palliative therapy, castration resistant prostate cancer/dt [Drug Therapy], chemotherapy induced nausea and vomiting/dt [Drug Therapy], chemotherapy induced nausea and vomiting/si [Side Effect], clinical pharmacy, controlled study, corticosteroid therapy, drug interaction, female, follow up, health care planning, human, influenza vaccination, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28684Test
Journal of Pharmacy Practice and Research
LibKey Link

مصطلحات الفهرس: coronary artery disease/si [Side Effect], drug indication, drug safety, female, heart failure/si [Side Effect], heart infarction/si [Side Effect], human, hypertension/si [Side Effect], male, meta analysis, multiple myeloma/dt [Drug Therapy], osteoclast, osteolysis, osteoporosis/dt [Drug Therapy], peripheral vascular disease/si [Side Effect], postmenopause, postmenopause osteoporosis/dt [Drug Therapy], prostate cancer/dt [Drug Therapy], randomized controlled trial (topic), risk factor, side effect/si [Side Effect], systematic review, vitamin supplementation, alendronic acid/ae [Adverse Drug Reaction], alendronic acid/cm [Drug Comparison], alendronic acid/dt [Drug Therapy], bisphosphonic acid derivative/ae [Adverse Drug Reaction], bisphosphonic acid derivative/cm [Drug Comparison], calcium, denosumab/ae [Adverse Drug Reaction], denosumab/cm [Drug Comparison], denosumab/dt [Drug Therapy], glucocorticoid, minodronic acid/ae [Adverse Drug Reaction], minodronic acid/cm [Drug Comparison], minodronic acid/dt [Drug Therapy], risedronic acid/ae [Adverse Drug Reaction], risedronic acid/cm [Drug Comparison], risedronic acid/dt [Drug Therapy], vitamin D, zoledronic acid/ae [Adverse Drug Reaction], zoledronic acid/cm [Drug Comparison], zoledronic acid/dt [Drug Therapy], rheumatoid arthritis/dt [Drug Therapy], acute coronary syndrome/si [Side Effect], acute heart failure/si [Side Effect], acute heart infarction/si [Side Effect], article, atrial fibrillation/si [Side Effect], bone density, bone metastasis/dt [Drug Therapy], brain hemorrhage/si [Side Effect], brain ischemia/si [Side Effect], breast cancer/dt [Drug Therapy], cardiovascular disease/si [Side Effect], cardiovascular effect, cardiovascular mortality, cerebrovascular accident/si [Side Effect], clinical outcome, congestive heart failure/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/27053Test
Journal of Bone and Mineral Research
LibKey Link

مصطلحات الفهرس: meta analysis, multiple myeloma/dt [Drug Therapy], observational study, oncology, ovary cancer/dt [Drug Therapy], peer review, phase 2 clinical trial (topic), phase 3 clinical trial (topic), priority journal, prostate cancer/dt [Drug Therapy], QT prolongation/si [Side Effect], randomized controlled trial (topic), review, systematic review, venous thromboembolism/si [Side Effect], abiraterone/ae [Adverse Drug Reaction], abiraterone/ct [Clinical Trial], abiraterone/dt [Drug Therapy], aflibercept/ae [Adverse Drug Reaction], aflibercept/ct [Clinical Trial], androgen receptor/ec [Endogenous Compound], axitinib/ae [Adverse Drug Reaction], axitinib/ct [Clinical Trial], bevacizumab/ae [Adverse Drug Reaction], bevacizumab/ct [Clinical Trial], bevacizumab/dt [Drug Therapy], cediranib/ae [Adverse Drug Reaction], cediranib/ct [Clinical Trial], cetuximab/ae [Adverse Drug Reaction], cetuximab/ct [Clinical Trial], cytochrome P450 family 17/ec [Endogenous Compound], enzalutamide/ae [Adverse Drug Reaction], enzalutamide/ct [Clinical Trial], enzalutamide/dt [Drug Therapy], epidermal growth factor receptor 2/ec [Endogenous Compound], estrogen receptor alpha/ec [Endogenous Compound], estrogen receptor beta/ec [Endogenous Compound], Flt3 ligand/ec [Endogenous Compound], lenalidomide/ae [Adverse Drug Reaction], lenalidomide/ct [Clinical Trial], lenalidomide/dt [Drug Therapy], nintedanib/ae [Adverse Drug Reaction], nintedanib/ct [Clinical Trial], panitumumab/ae [Adverse Drug Reaction], panitumumab/ct [Clinical Trial], pazopanib/ae [Adverse Drug Reaction], pazopanib/ct [Clinical Trial], platelet derived growth factor alpha receptor/ec [Endogenous Compound], platelet derived growth factor beta receptor/ec [Endogenous Compound], protein Ret/ec [Endogenous Compound], Raf protein/ec [Endogenous Compound], ramucirumab/ae [Adverse Drug Reaction], ramucirumab/ct [Clinical Trial], sorafenib/ae [Adverse Drug Reaction], sorafenib/ct [Clinical Trial], sorafenib/dt [Drug Therapy], sunitinib/ae [Adverse Drug Reaction], sunitinib/ct [Clinical Trial], tamoxifen/ae [Adverse Drug Reaction], tamoxifen/ct [Clinical Trial], tamoxifen/dt [Drug Therapy], thalidomide/ae [Adverse Drug Reaction], thalidomide/ct [Clinical Trial], thalidomide/dt [Drug Therapy], transcription factor/ec [Endogenous Compound], trastuzumab/ae [Adverse Drug Reaction], trastuzumab/ct [Clinical Trial], trastuzumab/dt [Drug Therapy], unclassified drug, vandetanib/ae [Adverse Drug Reaction], vandetanib/ct [Clinical Trial], vandetanib/dt [Drug Therapy], vasculotropin A/ec [Endogenous Compound], vasculotropin receptor 1/ec [Endogenous Compound], vasculotropin receptor 3/ec [Endogenous Compound], cytochrome P450 family 17a1/ec [Endogenous Compound], lymphoid transcription factor ikzf1/ec [Endogenous Compound], lymphoid transcription factor ikzf3/ec [Endogenous Compound], molecularly targeted therapy, arterial thromboembolism/si [Side Effect], breast cancer/dt [Drug Therapy], cardiology, cardiotoxicity/si [Side Effect], castration resistant prostate cancer/dt [Drug Therapy], clinician, Cochrane Library, cohort analysis, congestive heart failure/si [Side Effect], controlled study, drug megadose, Embase, female, general practice, heart left ventricle ejection fraction, human, hypertension/si [Side Effect], low drug dose, lung cancer/dt [Drug Therapy], male, Medline, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/27204Test
JNCI Cancer Spectrum
LibKey Link

مصطلحات الفهرس: drug absorption, drug bioavailability, drug contraindication, drug efficacy, drug metabolism, drug safety, erythema annulare centrifugum/si [Side Effect], erythema multiforme/si [Side Effect], eye examination, gastrointestinal symptom/si [Side Effect], giant cell granuloma/dt [Drug Therapy], glioblastoma/dt [Drug Therapy], glucose 6 phosphate dehydrogenase deficiency, granuloma annulare/dt [Drug Therapy], heart protection, heartburn/si [Side Effect], human, hyperpigmentation/si [Side Effect], hypertransaminasemia/si [Side Effect], hypoglycemia/si [Side Effect], immunomodulation, irritability, leukopenia/si [Side Effect], lichen (disease)/dt [Drug Therapy], lichen planus/dt [Drug Therapy], lichen sclerosus et atrophicus/dt [Drug Therapy], liver toxicity/si [Side Effect], lung cancer/dt [Drug Therapy], lupus vulgaris/dt [Drug Therapy], measles like rash/si [Side Effect], melanoma/dt [Drug Therapy], mood change, morphea/dt [Drug Therapy], mucinosis/dt [Drug Therapy], multiple myeloma/dt [Drug Therapy], nausea/si [Side Effect], necrobiosis lipoidica/dt [Drug Therapy], nightmare/si [Side Effect], nonhuman, outcome assessment, pancreas cancer/dt [Drug Therapy], panniculitis/dt [Drug Therapy], patient monitoring, pharmacodynamics, photodermatosis/dt [Drug Therapy], porphyria cutanea tarda/dt [Drug Therapy], practice guideline, pregnancy, prescription, pruritus/si [Side Effect], psoriasis/si [Side Effect], rash/si [Side Effect], retina maculopathy/si [Side Effect], retinopathy/si [Side Effect], review, risk benefit analysis, risk reduction, sarcoma/dt [Drug Therapy], side effect/si [Side Effect], skin contusion/si [Side Effect], skin sarcoidosis/dt [Drug Therapy], smoking, solid malignant neoplasm/dt [Drug Therapy], Stevens Johnson syndrome/si [Side Effect], systemic lupus erythematosus/dt [Drug Therapy], systemic sclerosis/dt [Drug Therapy], toxic epidermal necrolysis/si [Side Effect], treatment response, urticaria/si [Side Effect], vasculitis/dt [Drug Therapy], visual impairment/si [Side Effect], vomiting/si [Side Effect], cyclosporine/it [Drug Interaction], digoxin/it [Drug Interaction], glucose 6 phosphate dehydrogenase/ec [Endogenous Compound], hydroxychloroquine/ae [Adverse Drug Reaction], hydroxychloroquine/it [Drug Interaction], hydroxychloroquine/dt [Drug Therapy], hydroxychloroquine/pk [Pharmacokinetics], hydroxychloroquine/pd [Pharmacology], methotrexate/it [Drug Interaction], follicular mucinosis/dt [Drug Therapy], lichen planopilaris/dt [Drug Therapy], reticular erythematous mucinosis/dt [Drug Therapy], urticarial vasculitis/dt [Drug Therapy], laboratory test, abdominal distension/si [Side Effect], acute generalized exanthematous pustulosis/si [Side Effect], agranulocytosis/si [Side Effect], alopecia/si [Side Effect], alopecia areata/dt [Drug Therapy], anorexia/si [Side Effect], antineoplastic activity, antiphospholipid syndrome/dt [Drug Therapy], antithrombotic activity, aplastic anemia/si [Side Effect], blood toxicity/si [Side Effect], chronic urticaria/dt [Drug Therapy], dermatology, dermatomyositis/dt [Drug Therapy], diarrhea/si [Side Effect], DRESS syndrome/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35375Test
Australasian Journal of Dermatology
Click here for full text options
LibKey Link

مصطلحات الفهرس: drug absorption, drug bioavailability, drug contraindication, drug efficacy, drug metabolism, drug safety, erythema annulare centrifugum/si [Side Effect], erythema multiforme/si [Side Effect], eye examination, gastrointestinal symptom/si [Side Effect], giant cell granuloma/dt [Drug Therapy], glioblastoma/dt [Drug Therapy], glucose 6 phosphate dehydrogenase deficiency, granuloma annulare/dt [Drug Therapy], heart protection, heartburn/si [Side Effect], human, hyperpigmentation/si [Side Effect], hypertransaminasemia/si [Side Effect], hypoglycemia/si [Side Effect], immunomodulation, irritability, leukopenia/si [Side Effect], lichen (disease)/dt [Drug Therapy], lichen planus/dt [Drug Therapy], lichen sclerosus et atrophicus/dt [Drug Therapy], liver toxicity/si [Side Effect], lung cancer/dt [Drug Therapy], lupus vulgaris/dt [Drug Therapy], measles like rash/si [Side Effect], melanoma/dt [Drug Therapy], mood change, morphea/dt [Drug Therapy], mucinosis/dt [Drug Therapy], multiple myeloma/dt [Drug Therapy], nausea/si [Side Effect], necrobiosis lipoidica/dt [Drug Therapy], nightmare/si [Side Effect], nonhuman, outcome assessment, pancreas cancer/dt [Drug Therapy], panniculitis/dt [Drug Therapy], patient monitoring, pharmacodynamics, photodermatosis/dt [Drug Therapy], porphyria cutanea tarda/dt [Drug Therapy], practice guideline, pregnancy, prescription, pruritus/si [Side Effect], psoriasis/si [Side Effect], rash/si [Side Effect], retina maculopathy/si [Side Effect], retinopathy/si [Side Effect], review, risk benefit analysis, risk reduction, sarcoma/dt [Drug Therapy], side effect/si [Side Effect], skin contusion/si [Side Effect], skin sarcoidosis/dt [Drug Therapy], smoking, solid malignant neoplasm/dt [Drug Therapy], Stevens Johnson syndrome/si [Side Effect], systemic lupus erythematosus/dt [Drug Therapy], systemic sclerosis/dt [Drug Therapy], toxic epidermal necrolysis/si [Side Effect], treatment response, urticaria/si [Side Effect], vasculitis/dt [Drug Therapy], visual impairment/si [Side Effect], vomiting/si [Side Effect], cyclosporine/it [Drug Interaction], digoxin/it [Drug Interaction], glucose 6 phosphate dehydrogenase/ec [Endogenous Compound], hydroxychloroquine/ae [Adverse Drug Reaction], hydroxychloroquine/it [Drug Interaction], hydroxychloroquine/dt [Drug Therapy], hydroxychloroquine/pk [Pharmacokinetics], hydroxychloroquine/pd [Pharmacology], methotrexate/it [Drug Interaction], follicular mucinosis/dt [Drug Therapy], lichen planopilaris/dt [Drug Therapy], reticular erythematous mucinosis/dt [Drug Therapy], urticarial vasculitis/dt [Drug Therapy], laboratory test, abdominal distension/si [Side Effect], acute generalized exanthematous pustulosis/si [Side Effect], agranulocytosis/si [Side Effect], alopecia/si [Side Effect], alopecia areata/dt [Drug Therapy], anorexia/si [Side Effect], antineoplastic activity, antiphospholipid syndrome/dt [Drug Therapy], antithrombotic activity, aplastic anemia/si [Side Effect], blood toxicity/si [Side Effect], chronic urticaria/dt [Drug Therapy], dermatology, dermatomyositis/dt [Drug Therapy], diarrhea/si [Side Effect], DRESS syndrome/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35375Test
Australasian Journal of Dermatology
LibKey Link

مصطلحات الفهرس: pruritus/si [Side Effect], randomized controlled trial, rash/si [Side Effect], respiratory failure/si [Side Effect], rhabdomyolysis/si [Side Effect], sepsis/si [Side Effect], Stevens Johnson syndrome/si [Side Effect], survival analysis, systemic lupus erythematosus/si [Side Effect], toxic hepatitis/si [Side Effect], treatment duration, adrenal insufficiency/si [Side Effect], aged, anemia/si [Side Effect], article, backache/si [Side Effect], cardiopulmonary insufficiency/si [Side Effect], chromosome analysis, colitis/si [Side Effect], computer assisted tomography, constipation/si [Side Effect], controlled study, coughing/si [Side Effect], decreased appetite/si [Side Effect], dermatitis/si [Side Effect], diarrhea/si [Side Effect], disease exacerbation/si [Side Effect], drug efficacy, drug eruption/si [Side Effect], drug safety, drug withdrawal, dry skin/si [Side Effect], dyspnea/si [Side Effect], erythema/si [Side Effect], erythema multiforme/si [Side Effect], fatigue/si [Side Effect], female, fever/si [Side Effect], Food and Drug Administration, health care quality, heart arrest/si [Side Effect], heart failure/si [Side Effect], human, hypersensitivity/si [Side Effect], hyperthyroidism/si [Side Effect], hypokalemia/si [Side Effect], hypothyroidism/si [Side Effect], infusion related reaction/si [Side Effect], insomnia/si [Side Effect], insulin dependent diabetes mellitus/si [Side Effect], intestine ischemia/si [Side Effect], intestine perforation/si [Side Effect], kidney failure/si [Side Effect], low drug dose, lung embolism/si [Side Effect], major clinical study, male, mortality rate, multicenter study, multiple myeloma/dt [Drug Therapy], myasthenia gravis/si [Side Effect], myocarditis/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], nuclear magnetic resonance imaging, open study, overall survival, pancreatitis/si [Side Effect], peripheral edema/si [Side Effect], phase 3 clinical trial, pneumonia/si [Side Effect], positron emission tomography, priority journal, progression free survival, quality of life assessment, upper gastrointestinal bleeding/si [Side Effect], upper respiratory tract infection/si [Side Effect], vomiting/si [Side Effect], dexamethasone/ae [Adverse Drug Reaction], dexamethasone/ct [Clinical Trial], dexamethasone/cb [Drug Combination], dexamethasone/dt [Drug Therapy], dexamethasone/po [Oral Drug Administration], dexamethasone/pv [Special Situation for Pharmacovigilance], lenalidomide/ae [Adverse Drug Reaction], lenalidomide/ct [Clinical Trial], lenalidomide/cb [Drug Combination], lenalidomide/dt [Drug Therapy], lenalidomide/po [Oral Drug Administration], lenalidomide/pv [Special Situation for Pharmacovigilance], pembrolizumab/ae [Adverse Drug Reaction], pembrolizumab/ct [Clinical Trial], pembrolizumab/cb [Drug Combination], pembrolizumab/dt [Drug Therapy], pembrolizumab/iv [Intravenous Drug Administration], pembrolizumab/pv [Special Situation for Pharmacovigilance], Article

URL: Click here for full text options
LibKey Link

مصطلحات الفهرس: neutropenia/si [Side Effect], priority journal, retrospective study, sepsis/si [Side Effect], thrombocytopenia/si [Side Effect], thrombosis/si [Side Effect], treatment response, unspecified side effect/si [Side Effect], bortezomib/cb [Drug Combination], bortezomib/dt [Drug Therapy], cisplatin/ae [Adverse Drug Reaction], cisplatin/cb [Drug Combination], cisplatin/dt [Drug Therapy], cisplatin/iv [Intravenous Drug Administration], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], dexamethasone/ae [Adverse Drug Reaction], dexamethasone/cb [Drug Combination], dexamethasone/dt [Drug Therapy], dexamethasone/po [Oral Drug Administration], etoposide/ae [Adverse Drug Reaction], etoposide/cb [Drug Combination], etoposide/dt [Drug Therapy], etoposide/iv [Intravenous Drug Administration], granulocyte colony stimulating factor/dt [Drug Therapy], lenalidomide/cb [Drug Combination], lenalidomide/dt [Drug Therapy], thalidomide/cb [Drug Combination], thalidomide/dt [Drug Therapy], tumor lysis syndrome/si [Side Effect], adult, advanced cancer/dt [Drug Therapy], advanced cancer/th [Therapy], aged, anemia/si [Side Effect], article, autologous stem cell transplantation, cancer combination chemotherapy, febrile neutropenia/dt [Drug Therapy], febrile neutropenia/pc [Prevention], febrile neutropenia/si [Side Effect], female, heart disease/si [Side Effect], herpes zoster/si [Side Effect], human, major clinical study, male, multiple cycle treatment, multiple myeloma/dt [Drug Therapy], multiple myeloma/th [Therapy], mycosis/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37228Test
Leukemia and Lymphoma
Click here for full text options
LibKey Link

مصطلحات الفهرس: cyclophosphamide, follicular lymphoma/dt [Drug Therapy], fludarabine, Fc receptor/ec [Endogenous Compound], cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine, acute lymphoblastic leukemia/dt [Drug Therapy], amino acid sequence, ANCA associated vasculitis/dt [Drug Therapy], antigen binding, antineoplastic activity, B cell lymphoma/dt [Drug Therapy], Burkitt lymphoma/dt [Drug Therapy], cancer immunization, cell killing, chronic lymphatic leukemia/dt [Drug Therapy], clinical trial (topic), complement dependent cytotoxicity, diffuse large B cell lymphoma/dt [Drug Therapy], down regulation, drug mechanism, drug receptor binding, event free survival, hematologic malignancy/dt [Drug Therapy], human, humoral immune deficiency/dt [Drug Therapy], idiopathic thrombocytopenic purpura/dt [Drug Therapy], immune response, immunomodulation, immunosuppressive treatment, lack of drug effect, leukemia/si [Side Effect], lymphocytic lymphoma/dt [Drug Therapy], lymphoproliferative disease/dt [Drug Therapy], marginal zone lymphoma/dt [Drug Therapy], molecularly targeted therapy, overall survival, partial drug response, pharmacokinetic parameters, progression free survival, protein degradation, protein expression, randomized controlled trial (topic), methotrexate, obinutuzumab/dt [Drug Therapy], ocrelizumab, ofatumumab/dt [Drug Therapy], rituximab/ae [Adverse Drug Reaction], rituximab/dt [Drug Therapy], tumor antigen/ec [Endogenous Compound], tumor necrosis factor/ec [Endogenous Compound], veltuzumab, CD20 antibody, B lymphocyte receptor/ec [Endogenous Compound], systemic lupus erythematosus/dt [Drug Therapy], smoldering multiple myeloma/dt [Drug Therapy], rheumatoid arthritis/dt [Drug Therapy], review, recombinant DNA technology, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/36922Test
Human Vaccines and Immunotherapeutics
Click here for full text options
LibKey Link